Co-Authors
This is a "connection" page, showing publications co-authored by SIQING FU and BEHRANG AMINI.
Connection Strength
0.037
-
First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. JCI Insight. 2017 Apr 20; 2(8).
Score: 0.037
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.